Selvakumar Elangovan

Associate Professor

Dr. Selvakumar Elangovan was graduated from the University of Madras in 2006 in the field of Biochemistry. Then, he did postdoctoral studies at New York Medical College, USA and Georgia Health Sciences University, Augusta, USA. He has studied the mechanisms of the chemopreventive effects of natural compounds during his postdoctoral studies at New York Medical College. During his tenure at Georgia Health Sciences University, he has extensively studied the molecular signaling mechanisms of breast cancer initiation, progression and metastasis. Dr. Selvakumar is currently studying the molecular mechanisms of breast cancer invasion and metastasis. He is specifically interested in the signaling pathways associated with the estrogen receptor alpha (ERα), estrogen-related receptor alpha (ERRα) and TGFβ. He is also studying the chemopreventive and anticancer mechanisms of natural and plant-derived compounds. Along with research, he is teaching biochemistry, molecular biology and enzymology subjects to Master’s students.

Profile Links

Email :
[email protected]
Scopus Id :
8700688400
Google Scholar :
https://scholar.google.com/citations?user=8sudoTMAAAAJ&hl=en

Social Links

Educational Qualification
PhD

Projects
  1. Role of estrogen-related receptor α (ERRα) on the self-renewal of breast cancer stem cells, and its implications in the chemoresistance; Funding agency: ICMR; Duration: 2020-2023.
  2. Role of estrogen-related receptor α (ERRα) in epithelial-mesenchymal transition and metastasis of breast cancer Funding agency: SERB, DST; Duration: 2018-2021.
  3. Effect of lipoic acid on radiation-induced TGFβ signalling in breast cancer cells; Funding agency: BRNS; DAE. Duration: 2016-2019.


Administrative Responsibility
Examinations in charge for School of Biotechnology

Memberships
  1. Member, American Association for Cancer Research, (AACR), Philadelphia, USA
  2. Member, The Indian Science Congress Association, Kolkata, India.

Journals/Conferences :
1. Tripathy, J., Chowdhury, A. R., Prusty, M., Muduli, K., Priyadarshini, N., K. Reddy, K. S., Banerjee, B., Elangovan, S. (2020). α-Lipoic acid prevents the ionizing radiation-induced epithelial-mesenchymal transition and enhances the radiosensitivity in breast cancer cells. European Journal of Pharmacology, 871, 172938.
2. Tripathy, J., Tripathy, A., Thangaraju, M., Suar, M., Elangovan, S. (2018). α-Lipoic acid inhibits the migration and invasion of breast cancer cells through inhibition of TGFβ signalling. Life Sciences, 207, 15-22.
3. Pathania, R., Ramachandran, S., Elangovan, S., Padia, R., Yang, P., Cinghu, Veeranan-Karmegam, R., Arjunan, P., Gnana-Prakasam, J., Fulzele, S., Pei, L., Chang, C., Choi, J., Shi, H., Manicassamy, S., Prasad, P., Sharma, S., Ganapathy, V., Jothi, R., Thangaraju, M. (2015). DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis. Nature Communications, 6, 6910.
4. Elangovan, S., Pathania, R., Ramachandran, S., Ananth, S., Padia, R. N., Lan, L., Singh, N., Martin, P. M., Hawthorn, L., Prasad, P.D., Ganapathy, V., Thangaraju, M. (2014). The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival. Cancer Research, 74, 1166-1178.
5. Elangovan, S., Pathania, R., Ramachandran, S., Ananth, S., Padia, R. N., Srinivas, S. R., Babu, E., Hawthorn, L., Schoenlein, P. V., Boettger, T., Smith, S. B., Prasad, P. D., Ganapathy, V., Thangaraju, M. (2013). Molecular mechanism of SLC5A8 inactivation in breast cancer. Molecular and Cellular Biology, 33, 3920-3935.
6. Coothankandaswamy, V., Elangovan, S., Singh, N., Prasad, P.D., Thangaraju, M., Ganapathy, V. (2013). The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function. Biochemical Journal, 450, 169-178.
7. Elangovan, S., Ramachandran, S., Venkatesan, N., Ananth, S., Gnana Prakasam, J. P., Martin, P. M., Browning, D. D., Schoenlein, P. V., Prasad, P. D., Ganapathy, V., Thangaraju, M. (2011). SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor α in breast cancer. Cancer Research, 71, 6654-6664.
8. Babu, E., Ramachandran, S., CoothanKandaswamy, V., Elangovan, S., Prasad, P.D., Ganapathy, V., Thangaraju, M. (2011). Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate. Oncogene, 30, 4026-4037.
9. Karunakaran, S., Ramachandran, S., Coothankandaswamy, V., Elangovan, S., Babu, E., Periyasamy-Thandavan, S., Gurav, A., Gnanaprakasam, J. P., Singh, N., Schoenlein, P. V., Prasad, P.D., Thangaraju, M., Ganapathy, V. (2011). SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. Journal of Biological Chemistry, 286, 31830-31838.
10. Selvakumar, E., Hsieh, T. C. (2008). Regulation of cell cycle transition and induction of apoptosis in HL-60 leukemia cells by lipoic acid: role in cancer prevention and therapy. Journal of Hematology & Oncology, 1, 4.